How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,911 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

241. PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Collaborator: Progenics Pharmaceuticals, Inc. Information provided by (Responsible Party): Edward Schaeffer, Northwestern University Study Details Study Description Go to Brief Summary: The purpose of this study is to gain understanding of how PET-MR (positron emission tomography-magnetic resonance imaging) using the substance 18F-DCFPyL (PyL) may help in diagnosing prostate cancer and in determining the stage of prostate cancer before surgery. Condition or disease Intervention/treatment Phase Prostate (...) PET/MRI for the Staging of Newly Diagnosed Prostate Cancer PET/MRI for the Staging of Newly Diagnosed Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. PET/MRI for the Staging of Newly

2018 Clinical Trials

242. Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer Full Text available with Trip Pro

Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer Ultrasmall superparamagnetic particles of iron oxide (USPIOs) imaged with magnetic resonance imaging (MRI) have been proposed as an experimental method for visualizing lymph node (LN) metastases. The method does not require ionizing radiation, yet can detect small nodes that are involved with metastases. USPIOs are naturally taken up by macrophages that deposit in the normal LN creating (...) a low signal region in normal areas; areas within the node that do not show this loss of signal are likely involved by tumor although there can be other causes (fibrosis or inflammation). However, the lack of approved USPIOs that are clinically available hinders adoption and larger studies. The proposed indications for USPIO MRI, including specific compounds and imaging methods are discussed.

2018 Translational andrology and urology

243. EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells Full Text available with Trip Pro

EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells To investigate the role of EphA2 in malignant cellular behavior in renal cell carcinoma (RCC) cells and whether FAK/RhoA signaling can act as downstream effectors of EphA2 on RCC cells.Expression of EphA2 protein in non-metastatic RCC (Caki-2 and A498), metastatic RCC cells (Caki-1 and ACHN), HEK-293 cells and prostate cancer cells (PC-3 and DU (...) plays a critical role in the malignant cellular behavior of RCC and appears to be functional particularly in the early stage of malignant progression of non-metastatic RCC.

2015 PloS one

244. Clinically Localized Prostate Cancer

and identifying optimal treatment, while considering such factors as disease stage, risk, volume, age, and performance status. The purpose of this American Society of Clinical Oncology (ASCO) guideline is to endorse the American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) guideline on Clinically Localized Prostate Cancer by Sanda et al, , which was published online in 2017 (available at ) and in print in 2018. This ASCO endorsement (...) POPULATION Section: The Clinically Localized Prostate Cancer guideline made recommendations according to shared decision making, cancer severity/risk group (very low– and low-risk disease, intermediate-risk disease, high-risk disease), recommended treatment approaches (active surveillance, prostatectomy, radiotherapy, cryosurgery, high intensity focal ultrasound/focal therapy), and outcome expectations and management (treatment-related adverse events and health-related quality of life, post-treatment

2018 American Society of Clinical Oncology Guidelines

245. Early Detection of Prostate Cancer

Early Detection of Prostate Cancer Prostate Cancer: Early Detection Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) and Quality of Care Accreditations and Reporting Patient Education Early Detection of Prostate Cancer (2018) Published 2013; Reviewed and Validity Confirmed 2018 The clinical guideline on Early Detection of Prostate Cancer discusses the detection of disease at an early, pre-symptomatic stage through the use of screening tools, such as PSA. Early detection allows for more conservative management, if needed, via means such as active surveillance and watchful waiting. [pdf] Panel Members H. Ballentine Carter

2018 American Urological Association

246. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Prostate Cancer: Hypofractionated Radiotherapy Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology (...) is considered low compared to most other neoplasms, with several estimates derived from large populations in the range of 100 to 200 cGy. 5-7 Unlike other solid tumors with higher alpha-beta ratios, the alpha-beta ratio of the adjacent dose-limiting normal structure, namely the rectum, has been estimated to be greater than that of prostate cancer itself. 8,9 An implication of this relationship is that hypofractionation - daily delivery of EBRT with fraction sizes >200 cGy - may further improve

2018 American Urological Association

247. Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Cancer Prostate Cancer: Castration Resistant Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students (...) and dangerous drug interactions. This document was amended in April 2014 and March 2015 to reflect literature that was released since the original publication of this guideline in May 2013. An additional amendment was conducted in 2018 to reflect new literature released related to the treatment of patients with non-metastatic castration-resistant prostate cancer. This document will continue to be periodically updated to reflect the growing body of literature related to this disease. Panel Members Michael S

2018 American Urological Association

248. Prostate Cancer

of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017. 73. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173: 1938. 74. Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol, 2005. 29: 1228 (...) confers greater risk of biochemical progression. Urology, 2004. 64: 551. 253. Ploussard, G., et al. The prognostic significance of bladder neck invasion in prostate cancer: is microscopic involvement truly a T4 disease? BJU Int, 2010. 105: 776. 254. Hoedemaeker, R.F., et al. Staging prostate cancer. Microsc Res Tech, 2000. 51: 423. 255. Stamey, T.A., et al. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol, 2000

2018 European Association of Urology

249. Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value

or more than $5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers. Matthew R. Smith, MD, PhD Director, Genitourinary Malignancies Program Massachusetts General Hospital Cancer Center Dr. Smith has received consulting income between $10,000 and $20,000 from Janssen Biotech, Inc. in the last 12 months. ©Institute for Clinical and Economic Review, 2018 Page iv Evidence Report - Antiandrogens for Nonmetastatic Castration-Resistant Prostate Cancer Return (...) , such as degarelix. 5 ADT is used in a number of clinical settings. 6 Prostate cancer that has not been treated with ADT or that is responding to ADT is called “castration sensitive”. Over time, most cancers that were castration sensitive become castration resistant. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that progresses clinically, radiographically, or biochemically despite ADT that has achieved low (castrate) levels of serum testosterone. 6 Patients with metastatic disease

2018 California Technology Assessment Forum

250. Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment

Specific Antigen, serum protein associated with prostate cancer QoL Quality of life RD Risk difference RCT Randomized controlled trial RT Radiotherapy RTOG Radiation Therapy Oncology Group criteria, a scoring schema for radiation toxicity rV Volume of rectal tissue receiving a particular dose of radiation. E.g. rv70 is the volume of rectum receiving a dose of 70 Gy SBRT Stereotactic body radiation therapy TAU MUHC Technology Assessment Unit TNM Tumor Node Metastasis- Cancer classification VMAT (...) prostate cancer with low to intermediate risk. Hypofractionated radiotherapy delivers the conventional radiation dose of EBRT in fewer daily treatments. Hence, a larger daily dose of radiation (>2 Gy) is delivered in comparison with conventional EBRT. Hypofractionation or dose-escalation seeks to achieve more accurate targeting of the tumor while simultaneously increasing the dose of radiation. 2-4 However, as the rectum is adjacent to the prostate, it receives a substantial amount of radiation; hence

2018 McGill TAU reports

251. MR guided biopsy procedures for diagnosis of prostate cancer

) or transperineal ultrasound guided biopsy (TPUSGB) using software fusion of previously acquired mpMRI images and ultrasound images. This method provides real-time ultrasound guidance but does not allow validation of the track of the biopsy needle through the identified mpMRI lesion as the MRI image is not live. MSAC noted that the application proposed these procedures would be used exclusively for the diagnosis of prostate cancer in patients who are likely to be at intermediate/high risk of the disease. MSAC (...) comparator (in Attachment) Type of economic evaluation Cost-utility Type of model 2 stage: 1) Decision tree for diagnostic accuracy of tests 2) Markov model for long-term effects of treatment and monitoring prostate cancer Sources of evidence ? Meta-analysis of diagnostic accuracy studies (Wegelin 2016) ? Clinical studies (Pokorny 2014) ? Registry data Starting age 65 years. Time horizon Lifetime (25 years) Outcomes QALYG, LYG, cost Methods used to generate results Cohort expected value analysis, Markov

2017 Medical Services Advisory Committee

252. Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management

Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management | Cancer Care Ontario Google Tag Manager You are using an outdated browser. We suggest you update your browser for a better experience. for update. Browse Guidelines Browse Pathway Maps Sort by You are here / / Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management Guidelines & Advice (...) Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management english Version: 2 ID: 17-3 Oct 2017 Type of Content: Guidelines & Advice, Clinical Document Status: Current Authors: J. Chin, J. Srigley, L.A. Mayhew, R.B. Rumble, C. Crossley, A. Hunter, N. Fleshner, B. Bora, R. McLeod, S. McNair, B. Langer, A. Evans, Prostate Cancer Surgery and Pathology Expert Panel Guideline Objective The objective of this document is to provide

2017 Cancer Care Ontario

253. Ablative techniques for the treatment of localised prostate cancer

of the prostate reproduce more rapidly than in a normal prostate, causing a tumour to develop. When the tumour is confined to the prostate gland it is considered to be localised. However, the cancer can metastasise to other parts of the body, particularly the bones and lymph nodes. 9 One of the symptoms of localised prostate cancer is difficulty passing urine, although the condition is often diagnosed at an asymptomatic stage, particularly when serum PSA levels are monitored. 10 Number of patients According (...) cryotherapy, irreversible electroporation, MRI-guided laser ablation and radiofrequency ablation, may address this clinical need, as there is some evidence that they have less toxicity than conventional therapies. However, the efficacy of these therapies is unclear, as several studies have shown high rates of persistent malignancy in the prostate glands so treated. Given that ablative techniques are offered as curative therapies for early prostate cancer and they are competing with well-established

2018 COAG Health Council - Horizon Scanning Technology Briefs

254. Non-FDG tracers for use in PET-CT for suspected recurrent prostate cancer

in using these tracers (G Gillen and J Owens, NHS Greater Glasgow and Clyde. Personal communication, 6 Sept 2016). Evidence on 11 C- acetate was excluded from this evidence note on the advice of Scottish PET-CT experts. Staging of prostate cancer typically involves the use of routine imaging techniques such as magnetic resonance imaging (MRI) and CT for localised disease and lymph node involvement, and isotope bone scan for the assessment of bone metastases. Non-FDG PET-CT is also used in staging (...) of prostate cancer and is reported to have greater diagnostic value in staging of suspected relapsed prostate cancer (restaging) compared with staging in primary disease 6 . This evidence note compares the clinical effectiveness and cost effectiveness of choline tracers and novel non-FDG tracers, specifically anti- 18 F-FACBC and 68 Ga-PSMA, in restaging patients with suspected recurrent prostate cancer who have received treatment with curative intent. Health technology description PET-CT is a non

2017 Evidence Notes from Healthcare Improvement Scotland

255. High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer

PSA) and the Phoenix definition (an increase of 2 ng/mL or more above the nadir PSA). The management of PCa depends on the TNM stage of the disease as well as both biochemical (e.g., PSA) and pathological information (e.g., Gleason score), which have prognostic value. The optimum treatment for a patient with PCa requires an assessment of the risk of both metastatic spread and local recurrence [12]. [A0025] – How is prostate cancer currently managed according to published guidelines and in practice (...) the disease, while preserving continence and, if possible, potency [1] (B0001). Radiation therapy (RT) is another definitive treatment strategy in which a therapeutic dose of radi- ation is delivered to the tumour (either as external beam, brachytherapy, or a combination of both) while minimising the radiation to normal tissue. External beam RT (EBRT) utilises an external source of radiation to treat the prostate gland and a margin of adjacent normal tissue. Brachy- therapy directly implants a radioactive

2018 EUnetHTA

256. Prostate Cancer: Screening

. The CAP trial was a cluster-randomized trial of a single invitation to PSA-based screening in the United Kingdom among 415,357 men. Overall, 34% of invited men received a valid PSA screening test. After a median follow-up of 10 years, there was no significant difference in prostate cancer mortality between the invited group and the control group (absolute risk, 0.30 per 1000 person-years vs 0.31 per 1000 person-years, respectively). Based on clinical stage, tumor grade, and PSA level, prostate cancer (...) that current evidence suggests that treatment of early-stage, screen-detected prostate cancer with radical prostatectomy or radiation therapy likely reduces risk of clinical progression and metastatic disease and may reduce prostate cancer mortality. More details about the effectiveness and adverse effects of active treatment are provided in the Discussion section. Active surveillance is a treatment approach that seeks to limit the harms of treatment by allowing men with apparent low-risk prostate cancer

2018 U.S. Preventive Services Task Force

257. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Full Text available with Trip Pro

Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) Staging Manual has been updated and improved to ensure the highest degree of clinical relevance and to improve its utility for patient evaluation and clinical research. Major changes include: 1) pathologically organ-confined disease is now considered pT2 (...) and is no longer subclassified by extent of involvement or laterality, 2) tumor grading now includes both the Gleason score (as in the seventh edition criteria) and the grade group (introduced in the eighth edition criteria), 3) prognostic stage group III includes select, organ-confined disease based on prostate-specific antigen and Gleason/grade group status, and 4) 2 statistical prediction models are included in the staging manual. The AJCC will continue to critically analyze emerging prostate cancer

2017 CA: a cancer journal for clinicians

258. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting. Full Text available with Trip Pro

in non-malignant tissue and decreased during cancer progression. High expression of Caveolin-1 in tumor stroma was associated with significantly longer cancer specific survival in prostate cancer patients. This association remained significant when Gleason score and local tumor stage were combined with Caveolin-1 in a Cox regression model. High stromal Caveolin-1 immunoreactivity in prostate tumors is associated with a favourable prognosis in prostate cancer patients managed by watchful waiting (...) High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting. In the present study we have investigated whether Caveolin-1 expression in non-malignant and malignant prostate tissue is a potential prognostic marker for outcome in prostate cancer patients managed by watchful waiting. Caveolin-1 was measured in prostate tissues obtained through transurethral resection of the prostate from 395 patients diagnosed

2016 PLoS ONE

259. [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer]

[Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer] Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer] Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging (...) of prostate cancer] Atienza Merino G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Atienza Merino G. Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata. [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer] Santiago de Compostela: Galician Agency

2013 Health Technology Assessment (HTA) Database.

260. Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy Full Text available with Trip Pro

Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy There is growing evidence supporting incorporating multiparametric (mp) magnetic resonance imaging (MRI) scans into risk stratification, active surveillance, and treatment paradigms for prostate cancer. The purpose of our study was to determine whether demographic disparities exist in staging MRI utilization for prostate cancer patients.An (...) across all risk groups and black or nonprivate insurance patients in the low risk group were less likely to undergo staging prostate MRI scans. Further research should investigate these differences to ensure equitable utilization across all demographic groups considering the burden of prostate cancer disparities.

2016 Advances in radiation oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>